15441-07-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Chlorosulfonyl-propionic acid methyl ester is used as an intermediate for the synthesis of various pharmaceuticals and biologically active molecules. Its reactivity and functional groups provide a platform for the creation of diverse chemical structures with potential applications in medicine.
Used in Agrochemical Production:
3-Chlorosulfonyl-propionic acid methyl ester is utilized as a key component in the production of agrochemicals, contributing to the development of effective and innovative solutions for agriculture.
Used in Organic Synthesis:
3-Chlorosulfonyl-propionic acid methyl ester is employed as a valuable building block in organic synthesis, enabling the creation of a wide range of chemical structures with potential applications in various fields, including medicine and agriculture.
Used in Drug Discovery and Synthetic Strategies:
3-Chlorosulfonyl-propionic acid methyl ester plays a crucial role in the development of new synthetic strategies and drug discovery efforts, facilitating the exploration of novel chemical entities and therapeutic agents.

Upstream product

• 71562-00-0 3-sulfo-propionic acid methyl ester 
• 29652-02-6 3-thiocyanatopropionic acid methyl ester 
• 2935-90-2 Methyl 3-mercaptopropionate 

Downstream Products

• 856811-63-7 3,3'-(2,4,6-trimethyl-m-phenylenedisulfamoyl)-di-propionic acid dimethyl ester 
• 15441-08-4 methyl 3-sulfamoylpropanoate 
• 61758-81-4 3-phenylsulfamoyl-propionic acid methyl ester 
• 111874-99-8 3-[2-(4-Chloro-phenyl)-ethylsulfamoyl]-propionic acid methyl ester 
• 111874-98-7 3-[2-(3-Chloro-phenyl)-ethylsulfamoyl]-propionic acid methyl ester 
• 137383-68-7 3-[N-(4-Fluoro-2-trifluoromethylphenyl)sulfamoyl]propionic Acid Methyl Ester 
• 189012-23-5 Methyl 3-[2-(2-phenylethoxy)ethylaminosulphonyl]propanoate 
• 189012-77-9 methyl 3-[2-[2-(4-methylphenyl)ethoxy]ethylaminosulphonyl]propanoate 
• 189012-84-8 methyl 3-[2-(2-phenyl-1-propoxy)ethylaminosulphonyl]propanoate 
• 189012-92-8 methyl 3-[2-(2-phenylthioethoxy)ethylaminosulphonyl]propanoate 
• 423767-62-8 3-{4-[4-((S)-2-Methyl-1-phenyl-propylcarbamoyl)-2-phenyl-quinolin-3-ylmethyl]-piperazine-1-sulfonyl}-propionic acid methyl ester 
• 1048041-28-6 3-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]propionic acid methyl ester 
• 1257867-16-5 C₄₇H₆₃NO₇S 
• 90030-48-1 sodium 3-methoxy-3-oxo-propane-1-sulfinate 

Relevant academic research and scientific papers

Iridinesulfonamide compound and use method thereof

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically-acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation-induced cancers.

AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES

The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type I (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration.

AMINOALCOHOL DERIVATIVES

The present invention relates to a compound of the formula [I]: wherein (a), in which -Y-, R4, R5 and R6 are4 R5each as defined in the description, etc., R1 is hydrogen, halogen, lower alkyl, hydroxy, etc., R2 is hydrogen, lower alkyl or hydroxy(lower)alkyl, R3 is hydrogen or an amino protective group, 20 R7 is hydrogen, lower alkyl, cyclo(lower)alkyl, lower R9 alkenyl, -Z-R9 or (b), in which -Z- is -0-, -S-, R9 -SO- or -SO2-, and each R9 is independently hydrogen, lower alkyl, cyclo(lower)alkyl, etc., and R8 is -D-E-R10, in which -D- is -CONHSO2- or -S02NHCO-, E is bond or lower alkylene, and R10is halogen, cyano, carboxy, etc., or a prodrug thereof or a salt thereof. The compound [I] of the present invention and pharmaceutically acceptable salts thereof are useful for the prophylactic and/or the therapeutic treatment of ulcer, overactive bladder, and the like.

Synthesis of Alkanesulphonyl Chlorides from Alkylcobaloximes and Trichloromethanesulphonyl Chloride

Alkyl- and substituted alkylcobaloximes react photochemically with trichloromethanesulphonyl chloride to give high yields of alkanesulphonyl chlorides. erythro-2-Phenylethylcobaloxime gives an equimolar mixture of erythro- and threo-2-phenylethanesulphonyl chloride and diastereoisomerically pure 1-phenylpropan-2-ylcobaloxime gives a 1:1 mixture of diastereoisomers of 1-phenylpropane-2-sulphonyl chloride.The reaction is believed to proceed through a non-chain process initiated by photolysis of the carbon-cobalt bond.The product alkanesulphonyl chloride is then formed, either by a direct attack of the alkyl radical on the sulphur of trichloromethanesulphonyl chloride, or through capture of the alkyl radical by sulphur dioxide and halogen abstraction by the so-formed alkanesulphonyl radical from trichloromethanesulphonyl chloride.The latter process seems the more likely.No evidence could be obtained for an intermolecular homolytic attack of trichloromethyl radicals on the saturated alkyl ligand.